- ICH GCP
- Register voor klinische proeven in de VS.
- Klinische proef NCT03935854
Impact van een ketogeen dieet op de metabole en psychiatrische gezondheid bij patiënten met een bipolaire of schizofrenieziekte
Impact van een koolhydraatarm, vetrijk, ketogeen dieet op obesitas, metabole afwijkingen en psychiatrische symptomen bij patiënten met een bipolaire of schizofrenieziekte: een pilotproef
To initiate a low-carbohydrate, high-fat (LCHF) or ketogenic dietary (KD) intervention among a cohort of outpatients with either schizophrenia or bipolar illness who also have metabolic abnormalities, overweight/obesity, and/or are currently taking psychotropic medications experiencing metabolic side effects.
Studie Overzicht
Toestand
Conditie
Interventie / Behandeling
Gedetailleerde beschrijving
Adults with mental illness represent a high-risk, marginalized group in the current metabolic and obesity epidemic. Among US adults with severe mental illness, metabolic syndrome are highly prevalent conditions having severe consequences, with patients estimated to die on average 25 years earlier than the general population largely of premature cardiovascular disease. Many psychiatric medications, particularly neuroleptics and mood stabilizers, may, in addition, contribute to metabolic side effects and weight gain. Low-carbohydrate high-fat (LCHF) or ketogenic diets (KD) have been shown to reduce cardiovascular risk in those with insulin resistance. Recent findings support the idea that bipolar disorder, along with other psychiatric diseases schizophrenia, may have roots of metabolic dysfunction: cerebral glucose hypometabolism, oxidative stress, as well as mitochondrial and neurotransmitter dysfunction which has downstream effects on synapse connections. A KD diet provides alternative fuel to the brain aside from glucose and is believed to contain beneficial neuroprotective effects, including stabilization of brain networks, reduction of inflammation and oxidative stress. The purpose of this study is to evaluate both the metabolic and psychiatric outcomes with a KD diet in this psychiatric population.
Studietype
Inschrijving (Werkelijk)
Fase
- Niet toepasbaar
Contacten en locaties
Studie Locaties
-
-
California
-
Stanford, California, Verenigde Staten, 94305
- Stanford University Department of Psychiatry & Behavioral Sciences
-
-
Deelname Criteria
Geschiktheidscriteria
Leeftijden die in aanmerking komen voor studie
Accepteert gezonde vrijwilligers
Geslachten die in aanmerking komen voor studie
Beschrijving
Inclusion Criteria:
- Age 18-75 years old
- Meet DSM V criteria for schizophrenia or bipolar disorder, any subtype, for > 1 year and clinically stable (with no hospitalization for past 3 months)
- Currently taking psychotropic medication and gained at least 5% weight since starting medication or have a BMI greater than or equal to 26 kg/m2 or presence of at least one metabolic abnormality (hypertriglyceridemia, insulin resistance, dyslipidemia, impaired glucose tolerance)
- Willing to consent to all study procedures and attend follow-up appointments and motivated to follow the dietary program.
- Sufficient control over their food intake to adhere to study diets.
- Willingness to regularly monitor blood pressure, glucose, dietary intake, and body weight over the 4-month trial
Exclusion Criteria:
-
Any subject pregnant or nursing
-
Comorbidity of developmental delay
-
Active substance abuse with illicit drugs or alcohol
-
In a current severe mood or psychotic state when entering the study that would prohibit compliance with study visits or dietary program.
-
Anyone who has been hospitalized or taken clozapine over the past 3 months
-
Inability to complete baseline measurements
-
Severe renal or hepatic insufficiency
-
Cardiovascular dysfunction, including diagnosis of:
- Congestive heart failure
- Angina
- Arrhythmias
- Cardiomyopathy
- Valvular heart disease
-
Any other medical condition that may make either diet dangerous as determined by the study medical team (e.g. anorexia nervosa)
Studie plan
Hoe is de studie opgezet?
Ontwerpdetails
- Primair doel: Behandeling
- Toewijzing: NVT
- Interventioneel model: Opdracht voor een enkele groep
- Masker: Geen (open label)
Wapens en interventies
Deelnemersgroep / Arm |
Interventie / Behandeling |
|---|---|
|
Experimenteel: Ketogenic Diet 16 Week Group
Patients follow ketogenic diet for 16 weeks, with monitoring of physical and psychological health and coaching support |
Low Carbohydrate, Moderate Protein, High Fat Ketogenic Dietary Intervention 16 weeks |
Wat meet het onderzoek?
Primaire uitkomstmaten
Uitkomstmaat |
Maatregel Beschrijving |
Tijdsspanne |
|---|---|---|
|
Change in heart rate from baseline
Tijdsspanne: Baseline, 16 weeks
|
Heart rate recorded at 9 visits during study |
Baseline, 16 weeks
|
|
Change in blood pressure from baseline
Tijdsspanne: Baseline, 16 weeks
|
Blood pressure recorded at 9 visits during study |
Baseline, 16 weeks
|
|
Change in weight from baseline
Tijdsspanne: Baseline, 16 weeks
|
Weight recorded at 9 visits during study |
Baseline, 16 weeks
|
|
Change in waist circumference from baseline
Tijdsspanne: Baseline, 16 weeks
|
waist circumference measured at 9 visits during study |
Baseline, 16 weeks
|
|
Change in visceral fat mass from baseline
Tijdsspanne: Baseline, 16 weeks
|
Body composition (SECA) recorded at 5 visits during study |
Baseline, 16 weeks
|
|
Change in body fat mass from baseline
Tijdsspanne: Baseline, 16 weeks
|
Body composition (SECA) recorded at 5 visits during study |
Baseline, 16 weeks
|
|
Percent Change in Hemoglobin A1c from baseline
Tijdsspanne: Baseline, 16 weeks
|
Hemoglobin A1c recorded at initial and final visits |
Baseline, 16 weeks
|
|
Change in insulin resistance measure (HOMA-IR) from baseline
Tijdsspanne: Baseline, 16 weeks
|
HOMA-IR measured at initial and final visits |
Baseline, 16 weeks
|
|
Change in inflammatory marker (hsCRP) from baseline
Tijdsspanne: Baseline, 16 weeks
|
hsCRP measured at initial and final visits |
Baseline, 16 weeks
|
|
Change in lipid profile TG (triglycerides) from baseline
Tijdsspanne: Baseline, 16 weeks
|
Lipid profile TG measured at initial and final visits |
Baseline, 16 weeks
|
|
Change in lipid profile small LDL (small dense LDL) from baseline
Tijdsspanne: Baseline, 16 weeks
|
Lipid profile small LDL measured at initial and final visits |
Baseline, 16 weeks
|
|
Change in lipid profile (HDL) from baseline
Tijdsspanne: Baseline,16 weeks
|
Lipid profile HDL measured at initial and final visits |
Baseline,16 weeks
|
Secundaire uitkomstmaten
Uitkomstmaat |
Maatregel Beschrijving |
Tijdsspanne |
|---|---|---|
|
Psychiatric Indices - Mood
Tijdsspanne: Baseline, 16 weeks
|
Change in Mood Qualitative Score (Clinical Mood Monitoring) from baseline |
Baseline, 16 weeks
|
|
Psychiatric Indices- Clinical Global Impression
Tijdsspanne: Baseline, 16 weeks
|
Change in Clinical Global Impression Scales (CGI) from baseline 1-7 scale. 1= not at all ill, 7= among the most extremely ill patients) |
Baseline, 16 weeks
|
|
Generalized Anxiety Disorder - GAD-7 Anxiety
Tijdsspanne: Baseline, 16 weeks
|
Change in Generalized Anxiety Symptom (GAD-7) scale from baseline. 0-15+ scale. (0= no anxiety, 15+= severe anxiety) |
Baseline, 16 weeks
|
|
Patient Health Questionnaire - PHQ-9 Depression
Tijdsspanne: Baseline, 16 weeks
|
Change in Patient Health Questionnaire (PHQ-9) from baseline. Score range 0-27 (0= no depression, 27= severe depression) |
Baseline, 16 weeks
|
|
Psychiatric Indices- Global Assessment of Functioning
Tijdsspanne: Baseline, 16 weeks
|
Change in Global Assessment of Functioning (GAF) Scale from baseline. 1-100 scale (1= persistent danger of hurting self or others, 100= superior functioning) |
Baseline, 16 weeks
|
|
Psychiatric Indices- Quality of Life
Tijdsspanne: Baseline, 16 weeks
|
Change in Manchester Quality of Life Scale (MANSA) from baseline. Range 12-84 (each of 12 outcomes rated from 1= could not be worse to 7= could not be better; <4= dissatisfied with QoL, >4= satisfied with QoL) |
Baseline, 16 weeks
|
|
Psychiatric Indices- BPRS
Tijdsspanne: Baseline, 16 weeks
|
Change in Brief Psychiatric Rating Scale (BPRS) from baseline. Score range 18-126. (For each of 18 symptoms, 1=symptom not present, 7= extremely severe) |
Baseline, 16 weeks
|
|
Pittsburgh Sleep Quality Index - PSQI
Tijdsspanne: Baseline, 16 weeks
|
Change in Pittsburgh Sleep Quality Index from baseline. 0-21 scale (<5=good sleeper; 5+= meaningfully disturbed sleep or poor sleeper) |
Baseline, 16 weeks
|
Medewerkers en onderzoekers
Sponsor
Onderzoekers
- Hoofdonderzoeker: Shebani Sethi, MD, Stanford University
Publicaties en nuttige links
Algemene publicaties
- Yu B, Ozveren R, Sethi Dalai S. Ketogenic diet as a metabolic therapy for bipolar disorder: Clinical developments. Submitted to Journal of Affective Disorders. Research Square preprint March 2020: DOI is: 10.21203/rs.3.rs-334453/v1
- Sarnyai Z, Kraeuter AK, Palmer CM. Ketogenic diet for schizophrenia: clinical implication. Curr Opin Psychiatry. 2019 Sep;32(5):394-401. doi: 10.1097/YCO.0000000000000535.
- Brietzke E, Mansur RB, Subramaniapillai M, Balanza-Martinez V, Vinberg M, Gonzalez-Pinto A, Rosenblat JD, Ho R, McIntyre RS. Ketogenic diet as a metabolic therapy for mood disorders: Evidence and developments. Neurosci Biobehav Rev. 2018 Nov;94:11-16. doi: 10.1016/j.neubiorev.2018.07.020. Epub 2018 Jul 31.
- Norwitz NG, Sethi S, Palmer CM. Ketogenic diet as a metabolic treatment for mental illness. Curr Opin Endocrinol Diabetes Obes. 2020 Oct;27(5):269-274. doi: 10.1097/MED.0000000000000564.
- Sethi S, Sinha A, Gearhardt AN. Low carbohydrate ketogenic therapy as a metabolic treatment for binge eating and ultraprocessed food addiction. Curr Opin Endocrinol Diabetes Obes. 2020 Oct;27(5):275-282. doi: 10.1097/MED.0000000000000571.
- Sethi S, Wakeham D, Ketter T, Hooshmand F, Bjornstad J, Richards B, Westman E, Krauss RM, Saslow L. Ketogenic Diet Intervention on Metabolic and Psychiatric Health in Bipolar and Schizophrenia: A Pilot Trial. Psychiatry Res. 2024 May;335:115866. doi: 10.1016/j.psychres.2024.115866. Epub 2024 Mar 20.
- Carmen M, Safer DL, Saslow LR, Kalayjian T, Mason AE, Westman EC, Sethi S. Treating binge eating and food addiction symptoms with low-carbohydrate Ketogenic diets: a case series. J Eat Disord. 2020 Jan 29;8:2. doi: 10.1186/s40337-020-0278-7. eCollection 2020.
Studie record data
Bestudeer belangrijke data
Studie start (Werkelijk)
Primaire voltooiing (Werkelijk)
Studie voltooiing (Werkelijk)
Studieregistratiedata
Eerst ingediend
Eerst ingediend dat voldeed aan de QC-criteria
Eerst geplaatst (Werkelijk)
Updates van studierecords
Laatste update geplaatst (Werkelijk)
Laatste update ingediend die voldeed aan QC-criteria
Laatst geverifieerd
Meer informatie
Termen gerelateerd aan deze studie
Aanvullende relevante MeSH-voorwaarden
- Bipolaire en aanverwante stoornissen
- Hersenziekten
- Ziekten van het centrale zenuwstelsel
- Ziekten van het zenuwstelsel
- Schizofreniespectrum en andere psychotische stoornissen
- Psychische aandoening
- Voedingsstoornissen
- Metabole ziekten
- Overvoeding
- Lichaamsgewicht
- Veranderingen in lichaamsgewicht
- Glucosemetabolismestoornissen
- Stemmingsstoornissen
- Insuline-resistentie
- Hyperinsulinisme
- Overgewicht
- Pathologische aandoeningen, tekenen en symptomen
- Voedings- en stofwisselingsziekten
- Tekenen en symptomen
- Schizofrenie
- Obesitas
- Bipolaire stoornis
- Metaboolsyndroom
- Gewichtstoename
- Hersenziekten, Metabool
- Therapeutica
- Dieet, voedsel en voeding
- Fysiologische fenomenen
- Nutritionele fysiologische fenomenen
- Dieettherapie
- Voedingstherapie
- Dieet
- Dieet, koolhydraat-beperkt
- Dieet, ketogeen
Andere studie-ID-nummers
- 48527
Plan Individuele Deelnemersgegevens (IPD)
Bent u van plan om gegevens van individuele deelnemers (IPD) te delen?
Informatie over medicijnen en apparaten, studiedocumenten
Bestudeert een door de Amerikaanse FDA gereguleerd geneesmiddel
Bestudeert een door de Amerikaanse FDA gereguleerd apparaatproduct
Deze informatie is zonder wijzigingen rechtstreeks van de website clinicaltrials.gov gehaald. Als u verzoeken heeft om uw onderzoeksgegevens te wijzigen, te verwijderen of bij te werken, neem dan contact op met register@clinicaltrials.gov. Zodra er een wijziging wordt doorgevoerd op clinicaltrials.gov, wordt deze ook automatisch bijgewerkt op onze website .